53943-88-7

Basic information

• Product Name: Letosteine
• Synonyms: 2-[2-(2-Ethoxy-2-oxoethyl)sulfanylethyl]-1,3-thiazolidine-4-carboxylic acid;4-Thiazolidinecarboxylic acid, 2-[2-[(2-ethoxy-2-oxoethyl)thio]ethyl]-;Viscotiol;Visoctiol;2-[2-[(2-Ethoxy-2-oxoethyl)thio]ethyl]-4-thiazolidinecarboxylic acid;Letosteine
• CAS NO: 53943-88-7
• Molecular Formula: C₁₀H₁₇NO₄S₂
• Molecular Weight: 279.38
• EINECS: 258-879-3
• Product Categories: API
• Mol File: 53943-88-7.mol
• Article Data: 1

Chemical Properties

• Melting Point: 142°
• Boiling Point: 470 °C at 760 mmHg
• Flash Point: 238.1 °C
• Appearance: white crystalline powder
• Density: 1.284 g/cm³
• Vapor Pressure: 3.92E-10mmHg at 25°C
• Refractive Index: 1.547
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Dichloromethane (Slightly), DMSO (Slightly)
• PKA: 2.05±0.40(Predicted)
• CAS DataBase Reference: Letosteine(CAS DataBase Reference)
• NIST Chemistry Reference: Letosteine(53943-88-7)
• EPA Substance Registry System: Letosteine(53943-88-7)

Safety Data

• Hazardous Substances Data: 53943-88-7(Hazardous Substances Data)

Usage

Description

Letosteine, also known as a dicarboxylic acid monoester, is the monoethyl ester of 2-2-[(carboxymethyl)sulfanyl]ethyl-1,3-thiazolidine-4-carboxylic acid. It is a mucolytic agent that is utilized in the treatment of chronic bronchopneumopathies and related conditions.

Uses

Used in Pharmaceutical Industry:
Letosteine is used as a mucolytic agent for the treatment of chronic bronchopneumopathies and related conditions. It aids in breaking down and thinning mucus in the respiratory system, making it easier for patients to clear their airways and breathe more comfortably.
Used in Respiratory Treatment:
Letosteine is used as a therapeutic agent for respiratory conditions, specifically targeting chronic bronchopneumopathies. Its mucolytic properties help alleviate symptoms and improve the overall quality of life for patients suffering from these respiratory issues.

Originator

Viscotiol,Carlo Erba,France,1979

Manufacturing Process

In an Erlenmeyer flask placed in an ice bath, and under a well-ventilated hood, a solution of 0.1 mol of acrolein in 100 ml of ether was introduced, With the aid of a bromine ampoule, 0.1 mol (= 11 ml) of the ethyl ester of thioglycolic acid containing 0.5 ml of triethylamine was added drop by drop.One hour after completion of the addition, there was added 0.1 mol (15.6 g) of chlorhydrate of cysteine in alcoholic solution. The chlorhydrate of the expected derivative, which appeared in the form of a thick oil, was precipitated by addition of 0.1 mol (10 g) of potassium acetate in aqueous solution. The abundant precipitate obtained was filtered and washed in water and ether. The product was recrystallized in a minimum of absolute alcohol.

InChI:InChI=1/C10H17NO4S2/c1-2-15-9(12)6-16-4-3-8-11-7(5-17-8)10(13)14/h7-8,11H,2-6H2,1H3,(H,13,14)

Relevant articles and documents

Certain 2-(2-thioethyl)thiazolidine-4-carboxylic acids

The invention concerns new compounds for use in the pharmaceutical industry, its subject-matter being (thio-2-ethyl)-2 carboxy-4 thiazolidinic compounds of the general formula: STR1 where R is selected from hydrogen atom, alkyl, phenyl, alkylaryl and acyl radicals, heterocyclic groups such as pyridoxazole or benzimidazole, and alkyl- carboxylic groups, particularly acetic, and esters and amide derivatives thereof, and salts of addition of the compounds. These compounds are of use in the production of medicines with analgesic and mucolytic properties.